Stiff-Person Syndrome
The Neurologist 10:131-137, Murinson,B.B., 2004
Do NMDA Antagonists Prevent Neuronal Injury? Yes
ARch Neurol 49:418-420, Albers,G.W.,et al, 1992
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: No
Stroke 40:3161-3162, 3163, Strauss,M. &Hall,A., 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: Yes
Stroke 40:3159-3160, 3163, Hackam,D., 2009
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Levodopa for the Treatment of Parkinsons Disease
NEJM 359:2468-2476, LeWitt,P.A., 2008
Potassium Channel Antibody-Associated Encephalopathy: A Potentially Immunotherapy-Responsive Form of Limbic Encepahlitis
Brain 127:701-712, Vincent,A.,et al, 2004
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
What Matters is Not the Differences Between Triptans, but the Differences Between Patients
Arch Neurol 58:1481-1482, Saper,J.R., 2001
Triptans Are All Different
Arch Neurol 58:1479-1480,1482, Rapoport,A.M.&Tepper,S.J., 2001
The Poisoned Patient with Altered Consciousness, Controversies in the Use of a"Coma Cocktail"
JAMA 274:562-569, Hoffman,R.S.&Goldfrank,L.R., 1995